Chemed Corporation reported second-quarter 2026 financial results, with consolidated revenue increasing 8.8% to $673.3 million and GAAP diluted EPS rising 43.7% to $5.13. The VITAS segment drove growth, posting an 11.9% increase in net patient revenue to $443.3 million and a 60.5% surge in net income to $61.3 million, while Roto-Rooter revenue grew 3.3% to $229.9 million. The company updated its full-year 2026 adjusted EPS guidance upward to a range of $25.00 to $25.75, reflecting VITAS outperformance and share repurchases. Chemed repurchased 210,000 shares for $89.8 million during the quarter and maintains $140.0 million in long-term debt under a new $450 million credit facility. Chemed operates in the healthcare and home services industries through its VITAS hospice care and Roto-Rooter plumbing subsidiaries.